These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29438046)

  • 1. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Portaccio E; Annovazzi P; Ghezzi A; Zaffaroni M; Moiola L; Martinelli V; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Bellantonio P; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
    Neurology; 2018 Mar; 90(10):e823-e831. PubMed ID: 29438046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Portaccio E; Moiola L; Martinelli V; Annovazzi P; Ghezzi A; Zaffaroni M; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Solaro C; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
    Neurology; 2018 Mar; 90(10):e832-e839. PubMed ID: 29438041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
    Peng A; Qiu X; Zhang L; Zhu X; He S; Lai W; Chen L
    J Neurol Sci; 2019 Jan; 396():202-205. PubMed ID: 30502611
    [No Abstract]   [Full Text] [Related]  

  • 6. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.
    Andersen JB; Sellebjerg F; Magyari M
    Eur J Neurol; 2023 Jan; 30(1):162-171. PubMed ID: 36098960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30).
    Valero-López G; Millán-Pascual J; Iniesta-Martínez F; Delgado-Marín JL; Jimenez-Veiga J; Tejero-Martín AB; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2022 Oct; 66():104038. PubMed ID: 35870370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use.
    Triplett JD; Vijayan S; Rajanayagam S; Tuch P; Kermode AG
    Mult Scler Relat Disord; 2020 May; 40():101961. PubMed ID: 32028118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
    Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 15. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
    Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
    Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.
    Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort.
    Boskovic R; Wide R; Wolpin J; Bauer DJ; Koren G
    Neurology; 2005 Sep; 65(6):807-11. PubMed ID: 16186517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Portaccio E; Pastò L; Razzolini L; Moiola L; Martinelli V; Annovazzi P; Ghezzi A; Zaffaroni M; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Gasperini C; Paolicelli D; Simone M; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Comi G; Filippi M; Trojano M; Amato MP
    Mult Scler; 2022 Nov; 28(13):2137-2141. PubMed ID: 35296189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
    Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
    Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    Heesen C; Kleiter I; Meuth SG; Krämer J; Kasper J; Köpke S; Gaissmaier W
    J Neurol Sci; 2017 May; 376():181-190. PubMed ID: 28431609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.